Please login to the form below

Not currently logged in
Email:
Password:

IL-17 inhibitor

This page shows the latest IL-17 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Amgen’s R&D chief Sean Harper retires to seek biotech post

Amgen’s R&D chief Sean Harper retires to seek biotech post

from biosimilars and newer drugs such as Novartis’fast-growing IL-17 inhibitor Cosentyx (secukinumab).

Latest news

  • GSK sells eczema and psoriasis drug to Dermavant for £250m GSK sells eczema and psoriasis drug to Dermavant for £250m

    The cut included IL-6 inhibitor sirukumab for rheumatoid arthritis, which left tapinarof as the lead candidate in its immuno-inflammation programme. ... In the case of psoriasis, that includes not only new therapies such as Novartis’IL-17 inhibitor

  • UK, Germany back routine use of J&J’s Tremfya UK, Germany back routine use of J&J’s Tremfya

    psoriasis therapies such as Novartis’fast-growing IL-17 inhibitor Cosentyx (secukinumab), which EvaluatePharma expects to become a $4.6bn product by 2022. ... Add in additional IL-17 inhibitors for Eli Lilly and Valeant and the market for biologics for

  • Lilly claims another EU okay for Taltz Lilly claims another EU okay for Taltz

    Lilly claims another EU okay for Taltz. The IL-17 inhibitor can be used alone or in combination with methotrexate for PsA patients. ... Eli Lilly’s new immunotherapy Taltz has picked up a second indication in Europe, with the EMA approving the IL-17

  • Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

    The two trials - SURPASS and EXCEED - will compare interleukin-17 antagonist Cosentyx (secukinumab) against TNF blocker adalimumab in ankylosing spondylitis and psoriatic arthritis, respectively. ... Cosentyx was the first IL-17 inhibitor to reach the

  • Janssen’s Tremfya cleared for European use Janssen’s Tremfya cleared for European use

    therapy. The drug is a follow-up for its IL-23/IL-12 inhibitor Stelara, which is facing competition from newer psoriasis drugs showing greater efficacies in clinical trials. ... However, only 49.7% and 46.8% of patients taking Humira achieved a PASI 90,

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics